Hypertension (HTN) is present in nearly 50 million individuals, or approximately 29% of the adult US population. The prevalence of HTN is higher in men, increases with age, and varies among ethnic groups. Alterations of left ventricular structure and function can be present in patients with HTN and accurately characterized by echocardiography. The presence of left ventricular hypertrophy with increased left ventricular mass has prognostic implications in patients with HTN.
1. Hajjar I, Kotchen TA:Trends in prevalence, awareness, treatment, and control of hypertension in the United States, 1988-2000. JAMA2003;290: 199-206.
2.
2. Vasan RS, Levy D:Rates of progression to hypertension among non-hypertensive subjects: implications for blood pressure screening. Eur Heart J2002;23: 1067-1070.
3.
3. Mostero A, D’Agostino RB, Silbershatz H, Sytkowski PA, Kannel WB, Grobbee DE, et al: Trends in the prevalence of hypertension, antihypertensive therapy, and left ventricular hypertrophy from 1950-1989. N Engl J Med1999;340: 1221-1227.
4.
4. Kannel W:Elevated systolic blood pressure as a cardiovascular risk factor. Am J Cardiol2000;85: 251-255.
6. Kaplan NM:Hypertensive and atherosclerotic cardiovascular disease. In Braunwald E (ed): Heart Disease: A Textbook of Cardiovascular Medicine. 6th ed.Philadelphia: W. B. Saunders, 2001, pp 941-994.
7.
7. An P, Rice T, Rao DC:A review of recent genetic epidemiological studies of blood pressure. Cardiovasc Rev Rep2000;21: 85-88.
8.
8. Gardin JM, Wagenknecht LE, Anton-Culver H, et al: Relationship of cardiovascular risk factors to echocardiographic left ventricular mass in healthy young black and white adult men and women. The CARDIA Study. Circulation1995;92: 380-387.
9.
9. Gottdiener JS, Reda DJ, Materson BJ, et al: Importance of obesity, race and age to the cardiac structural and functional effects of hypertension. J Am Coll Cardiol1994;24: 1492-1498.
10.
10. de Simone G, Daniels SR, Devereux RB, et al: Left ventricular mass and body size in normotensive adults: assessment of allometric relations and impact of overweight. J Am Coll Cardiol1992;20: 1251-1260.
11.
11. Devereux RB, Alonso DR, Lutas EM, et al: Echocardiographic assessment of left ventricular hypertrophy: comparison to necropsy findings. Am J Cardiol1986;57: 450-458.
12.
12. Levy D, Savage DD, Garrison RJ, Anderson KM, Feinlieb M, Castelli WP:Echocardiographic criteria for left ventricular hypertrophy: Framingham Heart Study. Am J Cardiol1987;59: 956-960.
13.
13. Reichek N, Helak J, Plappert T, St.John Sutton M, Weber KT:Anatomic validation of left ventricular mass estimates from two-dimensional echocardiography: initial results. Circulation1983;67: 348-352.
14.
14. Schiller NB, Skioldebrand CG, Schiller EJ, et al: Canine left ventricular mass estimation by two-dimensional echocardiography. Circulation1983;68: 210-216.
15.
15. Park SH, Shub C, Nobrega TP, Bailey KR, Seward JB:Two-dimensional echocardiographic calculation of left ventricular mass as recommended by the American Society of Echocardiography: correlation with autopsy and M-mode echocardiography. J Am Soc Echocardiogr1996;9: 119-128.
16.
16. Schiller NB, Shah PM, Crawford M, et al: Recommendations for quantification of the left ventricle by two-dimensional echocardiography. J Am Soc Echocardiogr1989;2: 358-367.
17.
17. Gaasch WH:Left ventricular radius to wall thickness ratio. Am J Cardiol1979;43: 1189-1194.
18.
18. Ganau A, Devereux RB, Roman MJ, et al: Patterns of hypertrophy and geometric remodeling in essential hypertension. J Am Coll Cardiol1992;19: 1550-1558.
19.
19. Levy D, Anderson KM, Savage DD, Kannel WB, Christiansen JC, Castelli WP:Echocardiographically detected left ventricular hypertrophy: prevalence and risk factors. The Framingham Heart Study. Ann Intern Med1988;108: 7-13.
20.
20. Hammond IW, Devereux RB, Alderman MH, et al: The prevalence and correlates of echocardiographic left ventricular hypertrophy among employed patients with uncomplicated hypertension. J Am Coll Cardiol1986;7: 639-650.
21.
21. Liebson PR, Grandits G, Prineas R, et al: Echocardiographic correlates of left ventricular structure among 844 mildly hypertensive men and women in the treatment of mild hypertension (TOMHS). Circulation1993;87: 476-486.
22.
22. Post WS, Larson MG, Levy D:Impact of left ventricular structure on the incidence of hypertension. The Framingham Heart Study. Circulation1994;90: 179-185.
23.
23. de Simone G, Devereuex RB, Roman MJ, Alderman MJ, Laragh JH:Relationship of obesity and gender to left ventricular hypertrophy in normotensive and hypertensive adults. Hypertension1994;23: 600-606.
24.
24. Zabalgoitia M, Oneschuk L, Mercado R:Does ethnicity affect left ventricular mass in essential hypertension. Cardiol Rev2000;17: 20-26.
25.
25. Mureddu G, de Simone G, Greco R, Rosato GF, Contaldo F:Left ventricular filling in arterial hypertension. Hypertension1997;29: 544-550.
26.
26. Palatini P, Frigo G, Vriz V, et al: Early signs of cardiac involvement in hypertension. Am Heart J2001;142: 1016-1023.
27.
27. Zabalgoitia M, Rahman UR, Haley WH, et al: Comparison in systemic hypertension of left ventricular mass and geometry with systolic and diastolic function in patients <65 to ≥ 65 years of age. Am J Cardiol1998;82: 604-608.
28.
28. Bella JN, Palmieiri V, Kitzman DW, et al: Gender difference in diastolic function in hypertension (The HyperGEN Study). Am J Cardiol2002;89: 1052-1055.
29.
29. Schannwell CM, Schneppenheim M, Plehn G, Marx R, Strauer BE:Left ventricular diastolic function in physiologic and pathologic hypertrophy. Am J Hypertens2002; 15: 513-517.
30.
30. Waggoner AD:Alternative approaches for the assessment of left ventricular diastolic function. J Diag Med Sonography2002;18: 218-230.
31.
31. Quinones MA, Otto CM, Stoddard M, Waggoner AD, Zoghbi WA:Recommendations for quantification of Doppler echocardiography: a report from the Doppler Quantification Task Force of the Nomenclature and Standards Committee of the American Society of Echocardiography. J Am Soc Echocardiogr2002;15: 167-184.
32.
32. Schillaci G, Pasqualini L, Verdecchia P, et al: Prognostic significance of left ventricular diastolic dysfunction in essential hypertension. J Am Coll Cardiol2002;39: 2005-2011.
33.
33. Levy D, Garrison RJ, Savage DD, Kannel WB, Castelli WP:Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Study. N Engl J Med1990;322: 1561-1566.
34.
34. Koren MJ, Devereux RB, Casale PN, Savage DD, Laragh JH:Relation of left ventricular mass and geometry to morbidity and mortality in uncomplicated essential hypertension. Ann Intern Med1991;114: 345-352.
35.
35. Krumholz HM, Larson M, Levy D:Prognosis of left ventricular geometric patterns in the Framingham Heart Study. J Am Coll Cardiol1995;25: 879-884.
36.
36. Liao Y, Cooper RS, Durazo-Arvizu R, Mensah GA, Ghali JK:Prediction of mortality risk by different methods of indexation for left ventricular mass. J Am Coll Cardiol1997;29: 641-647.
37.
37. Haider AW, Larson MG, Benjamin EJ, Levy D:Increased left ventricular mass and hypertrophy are associated with increased risk for sudden death. J Am Coll Cardiol1998;32: 1454-1459.
38.
38. Benjamin EJ, Levy D:Why is left ventricular hypertrophy so predictive of morbidity and mortality?Am J Med Sci1999;317: 168-175.
39.
39. Levy D, Larson MG, Vasan RS, Kannel WB, Ho KKL:The progression from hypertension to congestive heart failure. JAMA1996;275: 1557-1562.
40.
40. Schmieder RE, Martus P, Klingbeil A:Reversal of left ventricular hypertrophy in essential hypertension: a meta-analysis of randomized double-blind studies. JAMA1996;275: 1507-1513.
41.
41. Dahlof B, Permert K, Hansson L:Reversal of left ventricular hypertrophy in hypertension patients: a meta-analysis of 109 treatment studies. Am J Hypertens1992;5: 95-110.
42.
42. Gottdiener JS:Effect of echocardiography on clinical impact and patient outcome in hypertension. J Am Soc Echocardiogr1996;9: 585-590.
43.
43. Muiesan ML, Salvetti M, Rizzoni D, Monteduro C, Castellano M, Agabiti-Rosei E:Persistence of left ventricular hypertrophy is a stronger indicator of cardiovascular events than baseline left ventricular mass or systolic performance: 10 years of follow-up. J Hypertens1996; 14Suppl 5: S43-S49.
44.
44. Devereux RB, Agabiti-Rosei E, Dahlof B, et al: Regression of left ventricular hypertrophy as a surrogate endpoint for morbid events in hypertension treatment trials. J Hypertens1996;14Suppl 5: S95-S102.
45.
45. Sheps SG, Frohlich ED:Limited echocardiography for hypertensive left ventricular hypertrophy. Hypertension1997;29: 560-563.
